Cancer Vaccines Market, Pipeline Analysis Report 2020

June 2020 | 115 pages | ID: C11B00AA8E60EN
DPI Research

Abstracts

“Global Cancer Vaccines market size is expected to surpass US$ 8.5 Billion by 2025”

Report Scope:

• Detailed Insights of the Introduction to Cancer Vaccines and Mechanism of Cancer Vaccines
• The Market Size of the Global Cancer Vaccines Market with Five Years Forecast
• The Market Size of the 4 Leading Cancer Vaccines with Five Years Forecast
• Provides Comprehensive Insights on the Funding of the Cancer Vaccines Research
• Investigates the Key Growth Drivers and Restraints of the Global Cancer Vaccines Market
• Provides Key Trends with Respect to Collaboration Deals, Merger & Acquisitions, Partnership Deals, and Licensing Agreement
• Detailed Insights of the Regulatory Framework Including the Approval Process and an Overview of the Regulatory Authorities in the United States, EU, and Japan
• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Sales Value Analysis, and Recent Development
• An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

“Cancer Vaccines Market, Pipeline Analysis Report, 2020” provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market. The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the global cancer vaccines market. The report provides historical market data for 2015 – 2019, and forecasts from 2020 till 2025.

The report contains a granular evaluation of the prevailing enterprise conditions, market demands, reveal facts in the marketplace, revenues, and offers forecasts through 2025. The report presents clear perception into current and future developments of the global cancer vaccines market.

The report explores detailed insights into the introduction to cancer vaccines and the mechanism of cancer vaccines. The report additionally provides a detailed evaluation of the leading 4 key marketed cancer vaccines market assessments globally, data from 2015 to 2019, and forecasts to 2025. The report reviews a clear insight into the funding of the cancer vaccines studies. The report additionally investigates special insights about the regulatory landscape which include the approval system and an overview of the regulatory authorities in the United States, EU, and Japan.

Key developments of collaboration, partnerships, merger & acquisition, and licensing settlement are analyzed with details. The report additionally examines the principle marketplace growth drivers and restraining forces and also offers an all-round future outlook.

The report concludes with the profiles of the key players in the global cancer vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, vaccines revenue analysis, and recent development.

Other emerging players are making novel era-based vaccines that are in all possibility to have an effect on the market share during the forecast duration. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with the current stage of clinical evaluation, vaccines target, platform technology, and recent developments.

The following 4 leading vaccines of the global cancer vaccines market are detailed with market size and five-year forecast:

• Gardasil/Gardasil 9
• Cervarix
• Provenge
• Imlygic

The foremost companies dominating this market for its products, offerings, and non-stop product trends are:

• Amgen
• Merck & Co., Inc
• GlaxoSmithKline (GSK)
• Dendreon Pharmaceuticals (Sanpower Group)
• GeoVax,Inc
• Moderna, Inc
• Flow Pharma, Inc
• Polynoma LLC
• IO Biotech
• OncoPep, Inc
• Medigen, Inc
• ViciniVax
• ImmuneTune
• Treos Bio Limited
• EpiThany
• CureVac AG
• DCprime
• Vaximm AG
• AdaptVac
• MimiVax LLC
• Agenus, Inc
• AlphaVax, Inc
• Genexine
• GlobeImmune, Inc
• Ubivac, Inc
• Vaccinogen, Inc
• Genocea Biosciences, Inc
• Northwest Biotherapeutics, Inc
• OncBioMune Pharmaceuticals, Inc
• Inovio Pharmaceuticals, Inc
• Enochian Biosciences
• Eu Biologics Co., Ltd.
• EVOQ Therapeutics
• Heat Biologics, Inc
• Scancell Holdings PLC
• Anixa Biosciences, Inc
• PDC*line Pharma
• Elios Therapeutics, LLC
• OSE Immunotherapeutics

The Report Helps Solution the Following Questions:

• What is the current size of the overall global cancer vaccines market? How much will this market be worth from 2020 to 2025?
• What are the key marketed cancer vaccines? What are their revenue potentials to 2025?
• What are the main drivers and restraints in the global cancer vaccines market?
• What are the major deals happenings in the global cancer vaccines market?
• Who are the top market players and what are their happenings, vaccines revenue, current developments, and scenarios?
• What are some of the most prominent cancer vaccines currently in clinical development? What are their happenings, platform technology, and current developments?

Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION TO CANCER VACCINES

3. MECHANISM OF CANCER VACCINES

4. GLOBAL CANCER VACCINES MARKET SIZE AND FORECAST (2015 – 2025)

5. KEY MARKETED CANCER VACCINES MARKET VALUE (2015 – 2025)

5.1 Gardasil/Gardasil
5.2 Cervarix
5.3 Provenge
5.4 Imlygic

6. KEY MARKET DRIVERS AND INHIBITORS OF THE CANCER VACCINES MARKET

6.1 Key Market Drivers
6.2 Key Market Inhibitors

7. FUNDING IN THE CANCER VACCINES RESEARCH

8. MAJOR DEALS AND AGREEMENT HAPPENINGS IN THE CANCER VACCINES MARKET

8.1 Collaboration Deals
8.2 Licensing Agreement
8.3 Partnership Deals
8.4 Merger & Acquisitions

9. REGULATORY ENVIRONMENT – CANCER VACCINES APPROVAL PROCESS

9.1 United States
9.2 Europe
9.3 Japan

10. KEY PLAYERS ANALYSIS

10.1 Merck & Co., Inc.
  10.1.1 Business Overview
  10.1.2 Vaccines Portfolio
  10.1.3 Recent Development
10.2 GlaxoSmithKline (GSK)
  10.2.1 Business Overview
  10.2.2 Vaccines Portfolio
10.3 Dendreon Pharmaceuticals (Sanpower Group)
  10.3.1 Business Overview
  10.3.2 Vaccines Portfolio
  10.3.3 Recent Development
10.4 Amgen
  10.4.1 Business Overview
  10.4.2 Vaccines Portfolio
  10.4.3 Recent Development

11. EMERGING PLAYERS ANALYSIS

11.1 Genocea Biosciences,Inc
  11.1.1 Business Overview
  11.1.2 Promising Cancer Vaccines in the Clinical Development
  11.1.3 Recent Development
11.2 GeoVax, Inc
  11.2.1 Business Overview
  11.2.2 Promising Cancer Vaccines in the Clinical Development
  11.2.3 Recent Development
11.3 Moderna, Inc
  11.3.1 Business Overview
  11.3.2 Promising Cancer Vaccines in the Clinical Development
  11.3.3 Recent Development
11.4 Northwest Biotherapeutics, Inc
  11.4.1 Business Overview
  11.4.2 Promising Vaccines in the Clinical Development
  11.4.3 Recent Development
11.5 OncBioMune Pharmaceuticals, Inc
  11.5.1 Business Overview
  11.5.2 Promising Vaccines in the Clinical Development
  11.5.3 Recent Development
11.6 Inovio Pharmaceuticals, Inc
  11.6.1 Business Overview
  11.6.2 Promising Cancer Vaccines in the Clinical Development
  11.6.3 Recent Development
11.7 Enochian Biosciences
  11.7.1 Business Overview
  11.7.2 Promising Cancer Vaccines in the Clinical Development
11.8 Flow Pharma, Inc
  11.8.1 Business Overview
  11.8.2 Promising Cancer Vaccines in the Clinical Development
  11.8.3 Recent Development
11.9 Polynoma LLC
  11.9.1 Business Overview
  11.9.2 Promising Cancer Vaccines in the Clinical Development
  11.9.3 Recent Development
11.10 IO Biotech
  11.10.1 Business Overview
  11.10.2 Promising Cancer Vaccines in the Clinical Development
  11.10.3 Recent Development
11.11 Eu Biologics Co., Ltd.
  11.11.1 Business Overview
  11.11.2 Promising Cancer Vaccines in the Clinical Development
11.12 OncoPep, Inc
  11.12.1 Business Overview
  11.12.2 Promising Cancer Vaccines in the Clinical Development
  11.12.3 Recent Development
11.13 Medigen, Inc
  11.13.1 Business Overview
  11.13.2 Promising Cancer Vaccines in the Clinical Development
11.14 EVOQ Therapeutics
  11.14.1 Business Overview
  11.14.2 Promising Cancer Vaccines in the Clinical Development
11.15 Heat Biologics, Inc
  11.15.1 Business Overview
  11.15.2 Promising Cancer Vaccines in the Clinical Development
  11.15.3 Recent Development
11.16 ViciniVax
  11.16.1 Business Overview
  11.16.2 Promising Cancer Vaccines in the Clinical Development
11.17 ImmuneTune
  11.17.1 Business Overview
  11.17.2 Promising Cancer Vaccines in the Clinical Development
11.18 Elios Therapeutics LLC
  11.18.1 Business Overview
  11.18.2 Promising Cancer Vaccines in the Clinical Development
  11.18.3 Recent Development
11.19 Treos Bio Limited
  11.19.1 Business Overview
  11.19.2 Promising Cancer Vaccines in the Clinical Development
  11.19.3 Recent Development
11.20 Scancell Holdings PLC
  11.20.1 Business Overview
  11.20.2 Promising Cancer Vaccines in the Clinical Development
  11.20.3 Recent Development
11.21 EpiThany
  11.21.1 Business Overview
  11.21.2 Promising Cancer Vaccines in the Clinical Development
  11.21.3 Recent Development
11.22 CureVac AG
  11.22.1 Business Overview
  11.22.2 Promising Cancer Vaccines in the Clinical Development
  11.22.3 Recent Development
11.23 DCprime
  11.23.1 Business Overview
  11.23.2 Promising Cancer Vaccines in the Clinical Development
  11.23.3 Recent Development
11.24 Vaximm AG
  11.24.1 Business Overview
  11.24.2 Promising Cancer Vaccines in the Clinical Development
  11.24.3 Recent Development
11.25 Anixa Biosciences, Inc
  11.25.1 Business Overview
  11.25.2 Promising Cancer Vaccines in the Clinical Development
  11.25.3 Recent Development
11.26 AdaptVac
  11.26.1 Business Overview
  11.26.2 Promising Cancer Vaccines in the Clinical Development
  11.26.3 Recent Development
11.27 PDC*line Pharma
  11.27.1 Business Overview
  11.27.2 Promising Cancer Vaccines in the Clinical Development
  11.27.3 Recent Development
11.28 MimiVax LLC
  11.28.1 Business Overview
  11.28.2 Promising Cancer Vaccines in the Clinical Development
  11.28.3 Recent Development
11.29 Agenus, Inc
  11.29.1 Business Overview
  11.29.2 Promising Cancer Vaccines in the Clinical Development
11.30 AlphaVax, Inc
  11.30.1 Business Overview
  11.30.2 Promising Cancer Vaccines in the Clinical Development
11.31 Genexine
  11.31.1 Business Overview
  11.31.2 Promising Cancer Vaccines in the Clinical Development
  11.31.3 Recent Development
11.32 GlobeImmune, Inc
  11.32.1 Business Overview
  11.32.2 Promising Cancer Vaccines in the Clinical Development
11.33 Ubivac, Inc
  11.33.1 Business Overview
  11.33.2 Promising Cancer Vaccines in the Clinical Development
11.34 Vaccinogen, Inc
  11.34.1 Business Overview
  11.34.2 Promising Cancer Vaccines in the Clinical Development
11.35 OSE Immunotherapeutics
  11.35.1 Business Overview
  11.35.2 Promising Cancer Vaccines in the Clinical Development
  11.35.3 Recent Development

List Of Figures

LIST OF FIGURES:

Figure 4–1: Global Cancer Vaccines Market Size (Million US$), 2015 – 2019
Figure 4–2: Global Cancer Vaccines Market Forecast (Million US$), 2020 – 2025
Figure 5–1: Gardasil/Gardasil 9 Market Value Analysis (Million US$), 2015 – 2019
Figure 5–2: Gardasil/Gardasil 9 Market Value Forecast (Million US$), 2020 – 2025
Figure 5–3: Cervarix Market Value Analysis (Million US$), 2015 – 2019
Figure 5–4: Cervarix Market Value Forecast (Million US$), 2020 – 2025
Figure 5–5: Provenge Market Value Analysis (Million US$), 2015 – 2019
Figure 5–6: Provenge Market Value Forecast (Million US$), 2020 – 2025
Figure 5–7: Imlygic Market Value Analysis (Million US$), 2016 – 2019
Figure 5–8: Imlygic Market Value Forecast (Million US$), 2020 – 2025

List Of Tables

LIST OF TABLES:

Table 8–1: Collaboration Deals in the Cancer Vaccines Market
Table 8–2: Licensing Agreement in the Cancer Vaccines Market
Table 8–3: Partnership Deals in the Cancer Vaccines Market
Table 8–4: Merger & Acquisitions in the Cancer Vaccines Market
Table 9–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 11–1: Genocea Biosciences, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–2: GeoVax, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–3: Moderna, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–4: Northwest Biotherapeutics, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–5: OncBioMune Pharmaceuticals, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–6: Inovio Pharmaceuticals, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–7: Enochian Biosciences Promising Cancer Vaccines in the Clinical Development
Table 11–8: Flow Pharma, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–9: Polynoma LLC Promising Cancer Vaccines in the Clinical Development
Table 11–10: IO Biotech Promising Cancer Vaccines in the Clinical Development
Table 11–11: Eu Biologics Co., Ltd. Promising Cancer Vaccines in the Clinical Development
Table 11–12: OncoPep Promising Cancer Vaccines in the Clinical Development
Table 11–13: Medigen, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–14: EVOQ Therapeutics Promising Cancer Vaccines in the Clinical Development
Table 11–15: Heat Biologics, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–16: Vicinivax Promising Cancer Vaccines in the Clinical Development
Table 11–17: ImmuneTune Promising Cancer Vaccines in the Clinical Development
Table 11–18: Elios Therapeutics Promising Cancer Vaccines in the Clinical Development
Table 11–19: Treos Bio Limited Promising Cancer Vaccines in the Clinical Development
Table 11–20: Scancell Holdings PLC Promising Cancer Vaccines in the Clinical Development
Table 11–21: EpiThany Promising Cancer Vaccines in the Clinical Development
Table 11–22: CureVac AG Promising Cancer Vaccines in the Clinical Development
Table 11–23: DCprime Promising Cancer Vaccines in the Clinical Development
Table 11–24: Vaximm AG Promising Cancer Vaccines in the Clinical Development
Table 11–25: Anixa Biosciences, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–26: AdaptVac Promising Cancer Vaccines in the Clinical Development
Table 11–27: PDC*line Pharma Promising Cancer Vaccines in the Clinical Development
Table 11–28: MimiVax LLC Promising Cancer Vaccines in the Clinical Development
Table 11–29: Agenus, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–30: AlphaVax Promising Cancer Vaccines in the Clinical Development
Table 11–31: Genexine Promising Cancer Vaccines in the Clinical Development
Table 11–32: GlobeImmune, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–33: Ubivac Promising Cancer Vaccines in the Clinical Development
Table 11–34: Vaccinogen Promising Cancer Vaccines in the Clinical Development
Table 11–35: OSE Immunotherapeutics Promising Cancer Vaccines in the Clinical Development